Replimune’s RP1 received two complete response letters from the FDA. Two rejections. Most companies would have shelved the program and moved on. Instead, Replimune resubmitted, and on June 26 the FDA accepted the filing with a response target of August 2026. BioPharma Dive described the acceptance as “the latest example of changing attitudes at the FDA” and framed it as part of a broader pattern alongside the UniQure Huntington’s gene therapy reversal and the REGENXBIO Duchenne filing. Whether this represents a genuine philosophical shift under acting leadership or simply the absence of a strong commissioner pushing a particular regulatory agenda is an open question. But for companies with programs that were rejected or delayed over the past year, the signal is clear: resubmit. The door may be more open than it was.
Meanwhile, Definium Therapeutics closed an upsized $805 million public offering days after its Phase 3 MDD win. The European CHMP recommended revoking Tavneos marketing authorization—matching the FDA’s voluntary removal request over patient deaths. The EU opened an antitrust investigation into whether Sanofi disparaged a rival flu vaccine. And the Medicare GLP 1 Bridge program launches Wednesday.
Replimune RP1 BLA Accepted After Two CRLs
What Happened: The FDA accepted Replimune’s resubmitted BLA for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma, with a response expected by August 2026.
Why This Acceptance Matters Beyond One Drug
RP1 is an oncolytic immunotherapy designed to selectively replicate in and destroy tumor cells while simultaneously stimulating the immune system to mount an anti tumor response. The combination with nivolumab (a PD 1 checkpoint inhibitor) creates a dual mechanism: the virus attacks the tumor directly while the checkpoint inhibitor removes the brakes on the immune system’s natural cancer killing ability. If approved, this would be the first oncolytic virus therapy approved in combination with a checkpoint inhibitor for melanoma.
The backstory is what makes this acceptance significant. Two CRLs. Two separate rejections by the FDA, each identifying deficiencies that the agency believed prevented approval. For most programs, a second CRL is terminal. The cost of addressing regulatory concerns, running additional studies, and resubmitting a filing is enormous for a clinical stage biotech. The fact that Replimune persisted through two rejections and that the FDA accepted the third submission speaks to both the company’s conviction in its data and the agency’s willingness to reconsider under new leadership.
BioPharma Dive placed the acceptance in a broader context that includes the UniQure Huntington’s reversal (the FDA dropped its demand for additional trial data and accepted the existing dataset for accelerated approval) and the REGENXBIO Duchenne filing (the company is moving forward with a BLA filing after what BioSpace described as testing “the agency’s apparent newfound rare disease outlook”). Three programs. Three instances where the FDA moved from a restrictive position to a more constructive one. The pattern suggests that the acting leadership at CDER and CBER—Michael Davis and Karim Mikhail—may be taking a less confrontational approach to borderline applications than their predecessors.
The practical implication for the industry is meaningful. Companies with programs that received CRLs, refuse to file letters, or unexpected additional data demands during the Makary era should evaluate whether the regulatory environment has shifted enough to warrant resubmission or reengagement. The underlying data requirements have not changed—the FDA still requires robust evidence of safety and efficacy. But the willingness to engage constructively on filing strategies, accept available data rather than demanding additional trials, and reconsider previous positions appears to have improved.
The question is how long this window stays open. Acting leadership is temporary by definition. When a permanent commissioner is eventually nominated and confirmed (and Capital Alpha warned in May that the administration “might struggle to find a suitable candidate who will want the job”), the new appointee will set a regulatory tone that may or may not continue the current approach. Companies considering resubmission should move while the environment is favorable rather than waiting to see who the permanent commissioner will be.
For the oncolytic virus space specifically, an RP1 approval would be significant. The oncolytic virus field has struggled commercially despite the scientific promise. Amgen’s Imlygic (talimogene laherparepvec) was approved in 2015 for melanoma but achieved limited commercial success. An RP1 plus nivolumab combination approval would demonstrate that the second generation of oncolytic therapies—engineered for greater potency and combined with checkpoint inhibitors—can produce the clinical outcomes and the commercial trajectory that the first generation did not.
Our Pro brief analyzes what the RP1, UniQure, and REGENXBIO acceptances tell us about regulatory direction under acting leadership, and assesses which other programs may benefit from the shift. [Details below.]
Definium Raises $805M After Phase 3 Depression Win
What Happened: Definium Therapeutics closed an upsized public offering raising $805 million in gross proceeds on June 26, days after reporting positive Phase 3 data for DT120 in major depressive disorder that sent shares up 52%.
What $805M in a Single Offering Tells You
This is one of the largest follow on offerings by a clinical stage biotech in 2026. The raise reflects several things simultaneously: investor confidence in the Phase 3 MDD data, the commercial potential of a differentiated dosage form (orally disintegrating, no water needed) in the largest CNS market, and the strength of the current biotech capital markets.
The speed of the raise is notable. Positive Phase 3 data on June 24. Stock up 52%. $805 million offering closed on June 26. Two days from data to capital. That kind of execution is only possible when the capital markets are deeply liquid and institutional investors are prepared to commit hundreds of millions of dollars on the basis of a single Phase 3 readout.
Combined with the $4.1 billion in IPO proceeds across 13 companies, the $450 million in venture funding announced in a single week (five privately held biotechs, per BioPharma Dive), and the PwC assessment that the ecosystem is “back to full health,” the Definium offering confirms that the biotech capital markets are functioning at their strongest level since 2021. Money is flowing into clinical stage biotechs from every direction: venture, IPO, and follow on.
The $450 million venture week deserves attention on its own. Five companies raising a combined $450 million in a single week is one of the busiest periods for biotech venture funding since April. The pace of private investment matters because venture capital is the earliest stage of the capital cycle—the money that funds the companies that eventually become IPO candidates and acquisition targets. When venture is flowing at this volume, the pipeline of clinical stage companies available for M&A in 2027 and 2028 is being built right now.
The companies producing positive clinical data are being rewarded with capital at a pace and scale that enables rapid development. The Definium trajectory—Phase 3 data, 52% stock surge, $805 million offering in 48 hours—is the new standard for how clinical stage biotechs can capitalize on positive results in a healthy market.
CHMP Recommends Revoking Tavneos Marketing Authorization
What Happened: The European CHMP recommended that the marketing authorization for Amgen’s Tavneos (avacopan) for ANCA associated vasculitis be revoked.
Dual Regulatory Action on Both Sides of the Atlantic
This follows the FDA’s call for voluntary removal over patient deaths, which we covered on June 17. Having both the U.S. and European regulatory authorities move against the same drug within weeks of each other is unusual and reflects the severity of the safety concerns.
When we covered the FDA’s action, we noted that Amgen had commissioned an independent data analysis from Duke University researchers to challenge the FDA’s causal assessment. Amgen argued the patient deaths were attributable to the underlying disease or confounding factors rather than to Tavneos. The CHMP’s recommendation to revoke marketing authorization suggests that European regulators were not persuaded by the available safety data, regardless of what the Duke analysis may have shown.
For Amgen, losing Tavneos on both sides of the Atlantic would effectively end the drug’s commercial life. For ANCA associated vasculitis patients, the revocation would remove one of the few targeted treatment options available, forcing patients back onto corticosteroid based regimens with their own significant side effect burden.
The Tavneos situation is a reminder that approval is not permanent. Post market safety monitoring can identify risks that were not apparent in the controlled environment of clinical trials, and when those risks include patient deaths, regulators on both sides of the Atlantic will act decisively—even for rare disease drugs where treatment alternatives are limited.
EU Opens Antitrust Investigation into Sanofi Flu Vaccine Campaign
What Happened: The European Commission opened a formal antitrust investigation into whether Sanofi breached EU competition rules by disparaging the only rival flu vaccine recommended for vulnerable patients with risk factors.
Why This Matters: Antitrust investigations into pharmaceutical marketing practices are relatively rare at the European Commission level. The allegation—that Sanofi disparaged a competitor’s product rather than competing on clinical merits—reflects growing regulatory intolerance for anti competitive behavior in vaccine markets. For Sanofi, which is already navigating the riliprubart Phase 3 failure in CIDP and the approaching Dupixent patent cliff (with AbbVie’s $10.9 billion zumilokibart acquisition now positioning a direct competitor), the investigation adds another source of regulatory and reputational pressure.
The timing is also notable given the broader vaccine landscape. Moderna’s mRNA flu vaccine just cleared the FDA advisory committee. Lilly acquired three vaccine companies in May. The flu vaccine market is becoming more competitive, and the EU investigation signals that regulators will not tolerate incumbents using disparagement to protect market share against innovative challengers.
Medicare GLP 1 Bridge Launches Wednesday
The program launches July 1—two days from today. Both Lilly products (Foundayo for oral convenience, Zepbound for injectable efficacy) and both Novo products (oral Wegovy, injectable Wegovy) are covered at a $50 per month copay for eligible Medicare Part D beneficiaries.
This is the most significant expansion of obesity treatment access in Medicare’s history. For the approximately 65 million Medicare beneficiaries, GLP 1 therapy has been largely inaccessible due to cost—list prices of $500 to $1,000 per month made these drugs unaffordable for most seniors on fixed incomes. The Bridge program reduces the out of pocket cost to $50, a level comparable to typical generic drug copays.
Initial enrollment volume in the first days and weeks after July 1 will be the most closely watched data point in the GLP 1 space this summer. The enrollment pace will signal three things: the depth of pent up demand for GLP 1 therapy among Medicare beneficiaries, the operational readiness of the pharmacy and telehealth infrastructure to process enrollments, and the competitive dynamics between Lilly and Novo in a new patient population where both companies start with a level playing field (Lilly’s Zepbound coverage was restored after initially trailing Novo’s Medicare access).
The Bridge program was a core component of the MFN pricing framework negotiated earlier this year. It represents the trade: pharmaceutical companies accepted lower pricing in exchange for broader access. Wednesday will begin to show whether that trade produces the enrollment volume the program was designed to achieve.
Strategic Themes
1. The FDA’s Regulatory Posture Has Shifted Under Acting Leadership
Three programs. Three instances of the FDA moving from restrictive to constructive. UniQure’s Huntington’s filing accepted after the agency reversed its demand for additional data. REGENXBIO moving toward a Duchenne BLA filing under the agency’s “apparent newfound rare disease outlook.” Replimune’s RP1 accepted after two CRLs. The pattern does not mean the FDA has lowered its standards. It means the agency under acting leadership is approaching borderline applications with more willingness to engage rather than to reject. For companies that received unfavorable regulatory decisions in the past 18 months, this may be the window to reengage.
2. The CHMP Tavneos Recommendation Shows Post Market Safety Enforcement Is Getting Tougher Globally
U.S. voluntary removal request. European marketing authorization revocation recommendation. Both within weeks. Both for the same drug. Both over patient deaths. The dual action signals that post market safety enforcement is tightening on both sides of the Atlantic simultaneously. For pharmaceutical companies, the message is that approval does not provide permanent protection against withdrawal, and that safety signals identified post approval will be acted upon with increasing speed and coordination between regulatory authorities.
3. $805M in a Single Offering Confirms the Capital Markets Are Rewarding Clinical Success at Historic Pace
Phase 3 data on Tuesday. Stock up 52%. $805 million offering closed by Thursday. The speed and scale of capital deployment following positive clinical data is the clearest evidence that the biotech capital markets are fully healthy. Institutional investors are prepared to commit hundreds of millions of dollars within 48 hours of a Phase 3 readout. That level of market responsiveness enables drug developers to fund late stage development and commercialization without the dilution and delay that slower capital raising would impose.
4. Wednesday Is the Starting Gun for the Medicare GLP 1 Market
The Bridge program launches July 1. For the first time, Medicare beneficiaries will have access to both Lilly and Novo GLP 1 products at $50 per month. The initial enrollment data will tell us more about the real world demand for obesity treatment in the senior population than any survey, analyst model, or conference presentation has been able to provide. The GLP 1 market has been built on commercial and employer covered populations. Medicare adds 65 million beneficiaries. Wednesday is where that expansion begins.
Frequently Asked Questions
What happened with Replimune RP1?
The FDA accepted the resubmitted BLA for RP1 (oncolytic virus therapy) plus nivolumab in advanced melanoma after two previous CRLs. Response expected August 2026. BioPharma Dive called it “the latest example of changing attitudes at the FDA.”
What is the Definium offering?
$805 million in an upsized public offering closed June 26, days after positive Phase 3 data for DT120 in major depressive disorder (shares +52%). One of the largest clinical stage follow on offerings of 2026.
What is happening with Tavneos?
The European CHMP recommended revoking Tavneos (avacopan) marketing authorization for ANCA associated vasculitis. This follows the FDA’s voluntary removal request over patient deaths (June 17). Dual U.S./EU regulatory action against the same drug is unusual and reflects severe safety concerns.
What is the Sanofi investigation?
The European Commission opened a formal antitrust investigation into whether Sanofi disparaged a rival flu vaccine recommended for vulnerable patients. Anti competitive marketing investigations at the EC level are relatively rare.
When does the Medicare Bridge launch?
Wednesday, July 1. Both Lilly (Foundayo, Zepbound) and Novo (oral Wegovy, injectable Wegovy) products covered at $50 per month copay for Medicare Part D beneficiaries.
Where does Revolution’s filing stand?
Nearly four weeks post ASCO plenary. CNPV NDA filing still pending. Truist projects Q3 approval.
BioMed Nexus Pro — What Institutional Subscribers Are Reading Today
FDA Attitude Shift. We analyze what the RP1, UniQure, and REGENXBIO acceptances tell us about regulatory direction under acting CDER and CBER leadership, identify which other programs that received unfavorable decisions may benefit from the shift, and assess how long the window remains open before a permanent commissioner appointment.
Tavneos. We assess why dual U.S. and EU regulatory action on the same drug is rare, what it means for Amgen’s rare disease portfolio, and how the precedent affects post market safety enforcement expectations across the industry.
Medicare Bridge Launch. We detail the program structure, enrollment mechanics, and initial volume expectations for Wednesday’s launch, model the competitive dynamics between Lilly and Novo in the Medicare population, and identify the data points to watch in the first week.
Plus: Definium capital raise analysis, Sanofi antitrust implications, DeepHealth AI diagnostics, Revolution filing watch, and the full H2 catalyst calendar.
About BioMed Nexus
BioMed Nexus delivers institutional grade intelligence to biotech and pharma executives, investors, and clinicians. Our daily briefings and deep dive analyses cut through the noise to deliver the strategic insights that drive better decision making in the life sciences.
Subscribe to receive daily updates and gain access to BioMed Nexus Pro institutional intelligence briefs.
